CD8A and neoplasm: Thus, we took the following approach: (1) collect T cells from healthy HLA-homo volunteers; (2) expand tumor antigen-specific CD8 T cells from these T cells; (3) produce iPSCs by reprogramming the CD8 T cells; (4) regenerate CTLs from the iPSCs; and (5) inject them into an HLA-hetero cancer patient whose cancer cells express the same tumor antigen.